# U S Physical Therapy Inc: financial statements, quarterly

USPH · NYSE · CIK 885978 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/usph.md) · [Financials](/companies/usph/financials.md) · [Filings](/companies/usph/filings.md) · [Insiders](/companies/usph/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/usph/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [150](/filings/0001140361-24-045836.md) | [155 d](/filings/0001140361-26-007170.md) | [156](/filings/0001140361-25-018157.md) | [167](/filings/0001140361-25-029744.md) | [168](/filings/0001140361-25-041152.md) | [180 d](/filings/0001140361-26-007170.md) | [184](/filings/0001140361-26-020025.md) | [197](/filings/0001140361-26-031825.md) | [197](/filings/0001140361-25-041152.md) | [203 d](/filings/0001140361-26-007170.md) | [198](/filings/0001140361-26-020025.md) | [214](/filings/0001140361-26-031825.md) |
| Gross profit | $m | [27.9](/filings/0001140361-24-045836.md) | [30.5 d](/filings/0001140361-26-007170.md) | [28.4](/filings/0001140361-25-018157.md) | [33.9](/filings/0001140361-25-029744.md) | [29.1](/filings/0001140361-25-041152.md) | [32.5 d](/filings/0001140361-26-007170.md) | [31.1](/filings/0001140361-26-020025.md) | [41.6](/filings/0001140361-26-031825.md) | [36.9](/filings/0001140361-25-041152.md) | [40.1 d](/filings/0001140361-26-007170.md) | [32.8](/filings/0001140361-26-020025.md) | [41.9](/filings/0001140361-26-031825.md) |
| Selling, general and administrative | $m | [12.0](/filings/0001140361-24-045836.md) | [13.9 d](/filings/0001140361-26-007170.md) | [14.1](/filings/0001140361-25-018157.md) | [14.2](/filings/0001140361-25-029744.md) | [14.4](/filings/0001140361-25-041152.md) | [15.6 d](/filings/0001140361-26-007170.md) | [16.2](/filings/0001140361-26-020025.md) | [17.5](/filings/0001140361-26-031825.md) | [17.4](/filings/0001140361-25-041152.md) | [18.1 d](/filings/0001140361-26-007170.md) | [18.3](/filings/0001140361-26-020025.md) | [19.0](/filings/0001140361-26-031825.md) |
| Operating income | $m | [15.9](/filings/0001140361-24-045836.md) | [(2.4) d](/filings/0001140361-26-007170.md) | [14.9](/filings/0001140361-25-018157.md) | [15.6](/filings/0001140361-25-029744.md) | [12.8](/filings/0001140361-25-041152.md) | [19.7 d](/filings/0001140361-26-007170.md) | [19.6](/filings/0001140361-26-020025.md) | [24.9](/filings/0001140361-26-031825.md) | [25.3](/filings/0001140361-25-041152.md) | [16.8 d](/filings/0001140361-26-007170.md) | [12.5](/filings/0001140361-26-020025.md) | [21.9](/filings/0001140361-26-031825.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [3.6](/filings/0001140361-24-045836.md) | [1.4 d](/filings/0001140361-26-007170.md) | [3.1](/filings/0001140361-25-018157.md) | [3.1](/filings/0001140361-25-029744.md) | [2.6](/filings/0001140361-25-041152.md) | [5.8 d](/filings/0001140361-26-007170.md) | [3.9](/filings/0001140361-26-020025.md) | [4.9](/filings/0001140361-26-031825.md) | [5.2](/filings/0001140361-25-041152.md) | [5.8 d](/filings/0001140361-26-007170.md) | [2.4](/filings/0001140361-26-020025.md) | [4.2](/filings/0001140361-26-031825.md) |
| Net income | $m | [9.3](/filings/0001140361-24-045836.md) | [0.7 d](/filings/0001140361-26-007170.md) | [8.0](/filings/0001140361-25-018157.md) | [7.5](/filings/0001140361-25-029744.md) | [6.6](/filings/0001140361-25-041152.md) | [9.2 d](/filings/0001140361-26-007170.md) | [9.9](/filings/0001140361-26-020025.md) | [12.4](/filings/0001140361-26-031825.md) | [13.1](/filings/0001140361-25-041152.md) | [4.2 d](/filings/0001140361-26-007170.md) | [5.0](/filings/0001140361-26-020025.md) | [9.9](/filings/0001140361-26-031825.md) |
| Diluted EPS | $ per share | [0.51](/filings/0001140361-24-045836.md) | not reported | [0.46](/filings/0001140361-25-018157.md) | [0.47](/filings/0001140361-25-029744.md) | [0.39](/filings/0001140361-25-041152.md) | not reported | [0.80](/filings/0001140361-26-020025.md) | [0.58](/filings/0001140361-26-031825.md) | [0.48](/filings/0001140361-25-041152.md) | not reported | [(0.12)](/filings/0001140361-26-020025.md) | [0.25](/filings/0001140361-26-031825.md) |
| Basic EPS | $ per share | [0.51](/filings/0001140361-24-045836.md) | not reported | [0.46](/filings/0001140361-25-018157.md) | [0.47](/filings/0001140361-25-029744.md) | [0.39](/filings/0001140361-25-041152.md) | not reported | [0.80](/filings/0001140361-26-020025.md) | [0.58](/filings/0001140361-26-031825.md) | [0.48](/filings/0001140361-25-041152.md) | not reported | [(0.12)](/filings/0001140361-26-020025.md) | [0.25](/filings/0001140361-26-031825.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [148](/filings/0001140361-23-052081.md) | [153](/filings/0001140361-25-006750.md) | [132](/filings/0001140361-24-024976.md) | [113](/filings/0001140361-24-037313.md) | [117](/filings/0001140361-24-045836.md) | [41.4](/filings/0001140361-26-007170.md) | [39.2](/filings/0001140361-25-018157.md) | [34.1](/filings/0001140361-25-029744.md) | [31.1](/filings/0001140361-25-041152.md) | [35.6](/filings/0001140361-26-031825.md) | [28.4](/filings/0001140361-26-020025.md) | [24.9](/filings/0001140361-26-031825.md) |
| Current assets | $m | [228](/filings/0001140361-23-052081.md) | [233](/filings/0001140361-25-006750.md) | [221](/filings/0001140361-24-024976.md) | [202](/filings/0001140361-24-037313.md) | [205](/filings/0001140361-24-045836.md) | [138](/filings/0001140361-26-007170.md) | [145](/filings/0001140361-25-018157.md) | [141](/filings/0001140361-25-029744.md) | [138](/filings/0001140361-25-041152.md) | [140](/filings/0001140361-26-031825.md) | [139](/filings/0001140361-26-020025.md) | [140](/filings/0001140361-26-031825.md) |
| Total assets | $m | [997](/filings/0001140361-24-045836.md) | [997](/filings/0001140361-25-006750.md) | [1,017](/filings/0001140361-24-024976.md) | [1,023](/filings/0001140361-24-037313.md) | [1,029](/filings/0001140361-24-045836.md) | [1,167](/filings/0001140361-26-007170.md) | [1,180](/filings/0001140361-25-018157.md) | [1,180](/filings/0001140361-25-029744.md) | [1,196](/filings/0001140361-25-041152.md) | [1,204](/filings/0001140361-26-031825.md) | [1,242](/filings/0001140361-26-020025.md) | [1,249](/filings/0001140361-26-031825.md) |
| Current liabilities | $m | [82.4](/filings/0001140361-23-052081.md) | [102](/filings/0001140361-25-006750.md) | [103](/filings/0001140361-24-024976.md) | [107](/filings/0001140361-24-037313.md) | [115](/filings/0001140361-24-045836.md) | [116](/filings/0001140361-26-007170.md) | [124](/filings/0001140361-25-018157.md) | [119](/filings/0001140361-25-029744.md) | [115](/filings/0001140361-25-041152.md) | [139](/filings/0001140361-26-031825.md) | [117](/filings/0001140361-26-020025.md) | [110](/filings/0001140361-26-031825.md) |
| Total liabilities | $m | [342](/filings/0001140361-23-052081.md) | [345](/filings/0001140361-25-006750.md) | [345](/filings/0001140361-24-024976.md) | [353](/filings/0001140361-24-037313.md) | [358](/filings/0001140361-24-045836.md) | [408](/filings/0001140361-26-007170.md) | [421](/filings/0001140361-25-018157.md) | [414](/filings/0001140361-25-029744.md) | [414](/filings/0001140361-25-041152.md) | [434](/filings/0001140361-26-031825.md) | [459](/filings/0001140361-26-020025.md) | [482](/filings/0001140361-26-031825.md) |
| Long-term debt | $m | [141](/filings/0001140361-23-052081.md) | [139](/filings/0001140361-25-006750.md) | [137](/filings/0001140361-24-024976.md) | [136](/filings/0001140361-24-037313.md) | [133](/filings/0001140361-24-045836.md) | [143](/filings/0001140361-26-007170.md) | [157](/filings/0001140361-25-018157.md) | [152](/filings/0001140361-25-029744.md) | [151](/filings/0001140361-25-041152.md) | [153](/filings/0001140361-26-031825.md) | [194](/filings/0001140361-26-020025.md) | [215](/filings/0001140361-26-031825.md) |
| Current portion of debt | $m | [7.6](/filings/0001140361-23-052081.md) | [7.7](/filings/0001140361-25-006750.md) | [9.2](/filings/0001140361-24-024976.md) | [9.7](/filings/0001140361-24-037313.md) | [9.6](/filings/0001140361-24-045836.md) | [11.0](/filings/0001140361-26-007170.md) | [9.3](/filings/0001140361-25-018157.md) | [8.2](/filings/0001140361-25-029744.md) | [8.8](/filings/0001140361-25-041152.md) | [9.9](/filings/0001140361-26-031825.md) | [10.8](/filings/0001140361-26-020025.md) | [4.6](/filings/0001140361-26-031825.md) |
| Shareholders' equity | $m | [492](/filings/0001140361-23-052081.md) | [476](/filings/0001140361-25-006750.md) | [480](/filings/0001140361-24-024976.md) | [485](/filings/0001140361-24-037313.md) | [483](/filings/0001140361-24-045836.md) | [489](/filings/0001140361-26-007170.md) | [497](/filings/0001140361-25-018157.md) | [501](/filings/0001140361-25-029744.md) | [504](/filings/0001140361-25-041152.md) | [476](/filings/0001140361-26-031825.md) | [469](/filings/0001140361-26-020025.md) | [449](/filings/0001140361-26-031825.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [16.4 d](/filings/0001140361-24-045836.md) | [26.8 d](/filings/0001140361-26-007170.md) | [4.4](/filings/0001140361-25-018157.md) | [29.0 d](/filings/0001140361-25-029744.md) | [22.1 d](/filings/0001140361-25-041152.md) | [19.4 d](/filings/0001140361-26-007170.md) | [(4.7)](/filings/0001140361-26-020025.md) | [34.9 d](/filings/0001140361-26-031825.md) | [19.9 d](/filings/0001140361-25-041152.md) | [24.9 d](/filings/0001140361-26-007170.md) | [3.8](/filings/0001140361-26-020025.md) | [34.4 d](/filings/0001140361-26-031825.md) |
| Capital expenditure | $m | [2.6 d](/filings/0001140361-24-045836.md) | [2.2 d](/filings/0001140361-26-007170.md) | [1.8](/filings/0001140361-25-018157.md) | [2.3 d](/filings/0001140361-25-029744.md) | [2.5 d](/filings/0001140361-25-041152.md) | [2.5 d](/filings/0001140361-26-007170.md) | [2.6](/filings/0001140361-26-020025.md) | [3.3 d](/filings/0001140361-26-031825.md) | [4.3 d](/filings/0001140361-25-041152.md) | [3.9 d](/filings/0001140361-26-007170.md) | [5.4](/filings/0001140361-26-020025.md) | [5.4 d](/filings/0001140361-26-031825.md) |
| Dividends paid | $m | [6.4 d](/filings/0001140361-24-045836.md) | [6.4 d](/filings/0001140361-26-007170.md) | not reported | not reported | [6.6 d](/filings/0001140361-25-041152.md) | [6.6 d](/filings/0001140361-26-007170.md) | not reported | not reported | [6.8 d](/filings/0001140361-25-041152.md) | [6.8 d](/filings/0001140361-26-007170.md) | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.0](/filings/0001140361-23-052081.md) | [13.0](/filings/0001140361-24-024976.md) | [13.7](/filings/0001140361-24-037313.md) | [15.0](/filings/0001140361-24-045836.md) | [15.0](/filings/0001140361-25-018157.md) | [15.1](/filings/0001140361-25-029744.md) | [15.1](/filings/0001140361-25-041152.md) | [15.1](/filings/0001140361-26-020025.md) | [15.2](/filings/0001140361-26-031825.md) | [15.2](/filings/0001140361-25-041152.md) | [15.2](/filings/0001140361-26-020025.md) | [15.1](/filings/0001140361-26-031825.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,922,698 at 2026-08-07, from the cover of the [10-Q filed 2026-08-07](/filings/0001140361-26-031825.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.